Artificial intelligence (AI) has greatly accelerated the process of identifying and optimizing lead compounds, particularly in the face of escalating global viral threats. Researchers can use AI methods to quickly screen multimillion-compound libraries while simultaneously facilitating the de novo design of novel antiviral agents with enhanced efficacy. The success of the AI-driven approaches toward the identification of potent antiviral compounds highlights their importance in surmounting emerging viral challenges through a more cost-efficient pathway. By examining these advancements, this article provides case studies that demonstrate how AI-driven approaches can revolutionize antiviral drug development, offering a more efficient pathway to combat emerging viral challenges.